Introduction
============

Leprosy is a well-known chronic infectious disease that is caused by *Mycobacterium leprae* (*M. leprae*). It has a spectrum of cutaneous responses ranging from tuberculoid to lepromatous poles. The incidence of leprosy has declined worldwide after the introduction of multidrug therapy (MDT) by the World Health Organization (WHO) in 1982;[@b1-ccid-5-001] however, it is still a public health problem in many countries, which have a high rate of endemic infection.[@b2-ccid-5-001] This was an indicator to modify or change WHO MDT, aiming at a more effective, safe, compliant, and shorter-duration regimen that is free from the fear of the emergence of resistant lepra bacilli.[@b3-ccid-5-001]

Advances in, and deep understanding of, immunology, pathogenesis, and genetics of leprosy could improve the ability to fight against this potentially devastating infectious disease and may lead to the development of better protocols for treatment and prevention of the disease.[@b4-ccid-5-001] The status of dermal vasculature was considered an important underlying pathogenic factor in leprosy, and the study of dermal vascular changes in leprosy was a matter of interest in previous reports.[@b5-ccid-5-001] It was observed that there is narrowing, tortuosity, dilatation, or occlusion of the skin's blood vessels of lepromatous leprosy patients, especially those located in the extremities.[@b6-ccid-5-001]

It was proposed that there are two microvascular architectural patterns observed in cutaneous lesions of leprosy: a dense and tortuous mesh of microvessels among the granulomatous infiltrate in lepromatous leprosy and a microvessel network restricted to the periphery of the granulomas in tuberculoid leprosy.[@b7-ccid-5-001] Moreover, the proliferation and migration of endothelial cells result in the formation of new blood vessels from pre-existing vessels, a process that is known as angiogenesis, which has also been studied in leprosy. It was proposed that there is a significant correlation between angiogenesis and bacterial load in cutaneous lesions of lepromatous patients.[@b8-ccid-5-001]

In this study we assessed angiogenesis in lepromatous leprosy patients before and after treatment with MDT alone and in combination with minocycline, a drug known to have an antiangiogenic effect. Moreover, we correlated the changes in angiogenesis with the changes in bacterial density (BD) in the same cutaneous lesions.

Materials and methods
=====================

A multicenter study was carried out on 40 lepromatous leprosy patients recruited from the outpatient clinics of the Dermatology Departments in Al-Hussein, Tanta, and Al- Zahraa university hospitals, Egypt. The study was approved by the local ethical committee.

Patient selection and grouping
------------------------------

All the patients included were newly diagnosed, and none of them had received any treatment for leprosy prior to the commencement of the study. The diagnosis of leprosy was based on the clinical presentation of bilateral, symmetrical, nonscaly erythematous nodular skin lesions, which was confirmed by the detection of *M. leprae* in direct nasal or slit skin smear. Exclusion criteria included pregnancy, lactation, known hypersensitivity to any of the therapeutic drugs, and serious illness or bad general condition. Written consent was signed by each patient after full explanation of the nature of the study, expected benefits of treatment, and possible side effects.

Patients were categorized into two equal groups (A and B). Group A (n = 20) received WHO MDT in the form of monthly observed doses of rifampicin (600 mg) and clofazimine (300 mg) and an unobserved daily dose of dapsone (100 mg) and clofazimine (50 mg). Group B (n = 20) received WHO MDT therapy in addition to a monthly observed dose of minocycline (100 mg). Treatment was continued for 6 months.

Skin biopsy and processing
--------------------------

A 4 mm punch biopsy was taken from each patient before treatment and 6 months after. The first biopsy was usually taken from the largest nodular lesion, and the second biopsy was taken from nearly the same site. From each specimen, four sections (4 μm thick) were prepared -- one for routine hematoxylin and eosin staining for diagnosis and evaluation of the granulomatous reaction, one for modified Ziehl-Neelsen stain (Wade-Fite method) to record the BD (assessed by bacterial index \[BI\]), and two for immunohistochemical staining with anti-CD31 and anti-CD34 monoclonal antibodies to assess microvascular density (MVD).

Immunohistochemical staining
----------------------------

Immunohistochemical staining was performed using an avidin-biotin peroxidase complex method on formalin-fixed, paraffin-embedded tissue sections,[@b9-ccid-5-001] using a 1/50 dilution of monoclonal CD31 and CD34 antibodies (Dako, Glostrup, Denmark). Briefly, tissue sections were mounted on 3-aminopropyl-triethoxysilane-coated slides and dried overnight at room temperature. Subsequently, they were dewaxed in xylene and rehydrated in graded ethanol. After being rinsed with phosphate buffered saline, they were immersed in 0.01 mol/L citric acid titrated to pH 6.0 and heated twice for 10 minutes in a microwave oven. The primary antibodies were then incubated on the sections for 30 minutes. Diaminobenzidine was used as a chromagen, and the slides were counterstained with Mayer's hematoxylin.

Microvessel density was assessed by immunostaining for CD31 and CD34 according to Weidner.[@b10-ccid-5-001] Areas with higher vascularity (so-called hot-spots) were located at low magnification (×40) and then were counted at ×400 magnification. Each positive endothelial cell or group of cells in contact with a spot was counted as an individual vessel. The mean vessel count from three fields was used as CD34 microvessel density or CD31 microvessel density. The assessment of both BD and MVD was performed only in the dermal granuloma without assessment of the stromal changes.

Microscopic evaluation
----------------------

BD in each Wade-Fite stained specimen was assessed by BI following Ridley's logarithmic scale (from 1 to 6). The number of solid staining (viable) lepra bacilli was visually calculated in ten different high power fields (HPF), and the mean ± standard deviation (SD) was recorded.

Statistical analysis
--------------------

For quantitative data, the mean and SD were calculated. The difference between means was statistically analyzed using the Student's *t*-test. *P* \< 0.05 was considered statistically significant.

Follow-up of the patients
-------------------------

Follow-up of the patients was done monthly for observation of the monthly doses of treatment and recording of any side effects, complications, or lepra reaction. We reported two patients in Group A who developed erythema nodosum leprosum during the first month of treatment (2 and 3 weeks, respectively). The treatment was continued in both patients with the addition of oral corticosteroids (40 mg daily for 15 days then gradually withdrawn). Both patients showed significant relief of symptoms within 3 weeks. In Group B, no significant side effects or complications were encountered during the treatment period.

Results
=======

Clinical data and direct smear
------------------------------

Group A included 16 males and four females. Their ages ranged from 25 years to 53 years with a mean of 32 ± 4.5 years. Group B included 13 males and seven females. Their ages ranged from 28 years to 49 years with a mean of 34 ± 2.5 years. The duration of the disease ranged from 3 weeks to 11 months with a mean of 14 ± 3 weeks. In 29 patients (72.5%) skin lesions were located on the trunk and extremities, whereas in eleven patients (27.5%) the lesions were distributed mainly on the extremities. Facial involvement was reported in 13 patients (32.5%) and nerve thickening in 27 patients (67.5%). *M. leprae* were detected in 16 patients (40%) by nasal smear and in 24 patients (60%) by slit skin smears.

Microvascular density
---------------------

### CD31 immunohistochemistry

In Group A, the MVD (number of vessels \[v\]/HPF) ranged from 35 v/HPF to 43 v/HPF with a mean of 39.1 ± 3.1 before treatment, whereas after treatment the MVD decreased to 16.5 ± 2.7 (ranged from 13 v/HPF to 19 v/HPF). This reduction was statistically highly significant (*P* \< 0.001) ([Table 1](#t1-ccid-5-001){ref-type="table"}). In Group B, the MVD ranged from 35 v/HPF to 46 v/HPF with a mean of 38.3 ± 2.5 before treatment, which decreased to 7.6 ± 1.9 after treatment (ranged from 5 v/HPF to 10 v/HPF). This reduction was statistically highly significant (*P* \< 0.001) ([Table 2](#t2-ccid-5-001){ref-type="table"}).

### CD34 immunohistochemistry

In Group A, the mean MVD significantly decreased from 42.2 ± 3.1 before treatment ([Figure 1A](#f1-ccid-5-001){ref-type="fig"}) to 18.8 ± 2.4 after treatment ([Figure 1B](#f1-ccid-5-001){ref-type="fig"}) ([Table 1](#t1-ccid-5-001){ref-type="table"}). In Group B, the mean MVD significantly decreased from 43.7 ± 2.3 before treatment ([Figure 2A](#f2-ccid-5-001){ref-type="fig"}) to 11.5 ± 1.6 after treatment ([Figure 2B](#f2-ccid-5-001){ref-type="fig"}) ([Table 2](#t2-ccid-5-001){ref-type="table"}). There was a statistically significant higher reduction (*P* \< 0.001) in angiogenesis evaluated by both CD31 and CD34 markers in Group B compared with in Group A ([Table 3](#t3-ccid-5-001){ref-type="table"}).

Bacterial density
-----------------

In Group A, BI ranged from 4 (10--100 bacilli/HPF) to 6 (\>1000 bacilli/HPF) with a mean of 5.1 ± 0.4 before treatment, which was significantly decreased to 2.3 ± 0.4 after treatment ([Table 1](#t1-ccid-5-001){ref-type="table"}). In Group B, the mean BI significantly decreased from 4.9 ± 0.3 before treatment ([Figure 3A](#f3-ccid-5-001){ref-type="fig"}) to 1.4 ± 0.2 after treatment ([Figure 3B](#f3-ccid-5-001){ref-type="fig"}) ([Table 2](#t2-ccid-5-001){ref-type="table"}). There was a statistically significant higher reduction (*P* \< 0.001) in BD in Group B compared with in Group A ([Table 3](#t3-ccid-5-001){ref-type="table"}).

Discussion
==========

Angiogenesis is considered to be a fundamental event in many conditions. The major role of angiogenesis was reported in relation to neoplastic conditions and malignancies that need an ongoing blood supply to grow and expand.[@b11-ccid-5-001] Abnormal angiogenesis was also implicated in other conditions such as rheumatoid arthritis, inflammation, and degenerative eye conditions, in addition to many biological processes such as development, reproduction, and wound repair.[@b12-ccid-5-001] In dermatological disorders, angiogenesis was implicated mainly in psoriasis,[@b13-ccid-5-001] and to a lesser extent in skin aging and photoaging.[@b14-ccid-5-001]

Drugs that inhibit angiogenesis were used primarily in the treatment of malignancy. The role of these antiangiogenic or antivascular therapies in the treatment of cancer became important after the establishment of the relationship between angiogenesis and tumor growth.[@b15-ccid-5-001] Inhibition of angiogenesis growth factors and transfer of antiangiogenesis genes were proposed as basic mechanisms of antiangiogenic drugs.[@b16-ccid-5-001] The target receptors of antiangiogenic drugs include PtdIns- 4,5-P2 that regulate vessel stability,[@b17-ccid-5-001] vascular endothelial growth factor receptor key proteins,[@b18-ccid-5-001] and Cap43 calcium-inducible genes.[@b19-ccid-5-001]

There are certain drugs which have an antiangiogenic effect and are used in the treatment of some skin diseases, such as chloroquine, which was suggested to have a beneficial effect in the treatment of discoid lupus erythematosus due to its antiangiogenic properties.[@b20-ccid-5-001] Thalidomide also has an antiangiogenic effect and is currently used in the treatment of different dermatological conditions including lepra reaction,[@b21-ccid-5-001] sclerodermatous cutaneous reaction of graft versus host disease,[@b22-ccid-5-001] and Jessner's lymphocytic infiltration of the skin.[@b23-ccid-5-001]

Recently, rifampicin, which is a component of MDT for leprosy, was suggested to have promising antiangiogenic effects that may enable its use as an effective antitumor agent.[@b24-ccid-5-001] Minocycline was also reported as one of the drugs that inhibit angiogenesis,[@b25-ccid-5-001] and it is known to have an important role in the treatment of leprosy as a main component of rifampicin, ofloxacin, and minocycline (ROM) therapy.[@b26-ccid-5-001] However, the mechanism of action of both drugs in the treatment of leprosy remains unclear. Is it due to their antimicrobial effect only or due also to their antiangiogenic effect?

To our knowledge, no previous studies have evaluated the efficacy of these antiangiogenic drugs on angiogenesis in cutaneous lesions of lepromatous leprosy patients, but a few studies monitor angiogenesis in the spectrum of leprosy. Bhandarkar et al[@b8-ccid-5-001] studied angiogenesis in 32 leprosy patients using CD31 as a marker for microvessel density. The MVD of lepromatous leprosy lesions was (44.0 ± 9.8 v/HPF). We found a lower MVD value with a CD31 marker in lepromatous leprosy (39.1 ± 3.1 in Group A and 38.3 ± 2.5 in Group B), and with a CD34 marker we found a higher value (42.2 ± 3.1 in Group A and 43.7 ± 2.3 in Group B), which was close to that encountered by Bhandarkar et al. This may suggest the benefit of using more than one marker (CD31, CD34) in the assessment of angiogenesis.

Kim et al[@b27-ccid-5-001] also found a significant increase of MVD in lepromatous leprosy lesions compared with in normal skin, with an overall increase in the mean number of vessels from tuberculoid leprosy through borderline (tuberculoid and lepromatous) to lepromatous leprosy lesions. The MVD values in lepromatous leprosy were higher (104.40 ± 27.71) compared with our results. This can be explained by the use of a different vascular marker (Factor VIII-related antigen) or a different counting system.

These studies suggested that angiogenesis could be evaluated by using different vascular markers. In the current study we preferred to use two markers (CD31 and CD34) in the assessment of angiogenesis for proper evaluation of MVD and to minimize false positive results. Both CD31 and CD34 are known as effective markers in identifying blood vessels and were proposed also to be good prognostic markers of neoangiogenesis.[@b28-ccid-5-001],[@b29-ccid-5-001]

The significant reduction of MVD and BD in Group A, which was treated with MDT, may prove the possible anti-angiogenic effect of rifampicin in addition to its antimicrobial effect. Rifampicin was suggested to exert its antiangiogenic effect through inhibition of the expression of angiogenesis-associated genes with downregulation of proangiogenic genes and inhibition of microvascular endothelial cell proliferation.[@b24-ccid-5-001] In a manner comparable with the action of endostatin, the endogenous angiogenesis inhibitor is known to downregulate a variety of growth and angiogenesis-related genes in a wide range of endothelial lineage cells.[@b30-ccid-5-001]

In Group B, minocycline 100 mg, which is known to have antiangiogenic properties, was added to MDT as a monthly dose, aiming to potentiate the antiangiogenic efficacy of the classic MDT regimen. Although minocycline has different mechanisms of action from its antimicrobial properties, such as inhibition of collagenase activity,[@b31-ccid-5-001] and its anti-inflammatory effect through reduction of cytokines and pro-inflammatory protein expression,[@b32-ccid-5-001] it also possesses inhibitory properties of angiogenesis.[@b25-ccid-5-001] This antiangiogenic effect of minocycline may contribute to the direct inhibition of matrix metalloproteinase activity and also to the inhibition of vascular endothelial growth factor-induced smooth muscle cell migration.[@b33-ccid-5-001]

In the present work the reduction of MVD was significantly higher in Group B than in Group A using both markers. These results may suggest the presence of a synergistic effect of both minocycline and rifampicin as antiangiogenic drugs in addition to their antimicrobial effect. Moreover, the absence of any side effects or lepra reaction in Group B compared with in Group A may add a new benefit for the combination of MDT with minocycline.

Another important finding in this work is the significantly higher reduction in BI in Group B compared with in Group A. This may suggest that the addition of minocycline to the MDT can cause a more rapid elimination of lepra bacilli from cutaneous lesions of lepromatous leprosy patients. This rapid elimination of lepra bacilli from cutaneous lesions and also from mucous membranes is helpful in decreasing the transmission of the disease and maintaining the standard target of elimination of leprosy.

Conclusion
==========

To our knowledge, this is the first work that assesses angiogenesis in leprosy patients after treatment with antiangiogenic drugs. The synergistic antiangiogenic effect of both minocycline and rifampicin was found to be promising and effective in the treatment of leprosy. Moreover, this combination showed an advantage of rapid elimination of *M. leprae* from the cutaneous lesions of lepromatous leprosy patients and decreased the possibility of the occurrence of lepra reaction. We hope that this regimen will be considered in wide-scale studies, especially in endemic areas of leprosy.
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![CD34 immunostaining (Group A) shows high microvessel density before treatment (**A**) that decreased after treatment (**B**) (×100 and ×400).](ccid-5-001f1){#f1-ccid-5-001}

![CD34 immunostaining (Group B) shows high microvessel density before treatment (**A**) that significantly decreased after treatment (**B**) (×100 and ×400).](ccid-5-001f2){#f2-ccid-5-001}

![Fite stain (Group B) shows higher density of viable and intact *Mycobacterium leprae* before treatment (**A**) compared with a few and fragmented bacilli after treatment (**B**) (×1000).](ccid-5-001f3){#f3-ccid-5-001}

###### 

CD31 and CD34 immunostaining and BI before and after treatment in group A

  Marker             Before treatment   After treatment   *P*-value
  ------------------ ------------------ ----------------- ---------------------------------------------------
  **CD31 (v/HPF)**                                        
  Range              35--43             13--19            \<0.001[a](#tfn1-ccid-5-001){ref-type="table-fn"}
  M ± SD             39.1 ± 3.1         16.5 ± 2.7        
  **CD34 (v/HPF)**                                        
  Range              37--46             15--23            \<0.001[a](#tfn1-ccid-5-001){ref-type="table-fn"}
  M ± SD             42.2 ± 3.1         18.8 ± 2.4        
  **BI**                                                  
  Range              4--6               1--2              \<0.001[a](#tfn1-ccid-5-001){ref-type="table-fn"}
  M ± SD             5.1 ± 0.4          2.3 ± 0.4         

**Note:** *P* is significant at \<0.05.

**Abbreviations:** BI, bacterial index; M, mean; SD, standard deviation, v/HPF, vessel/high power field.

###### 

CD31 and CD34 immunostaining and BI before and after treatment in Group B

                     Before treatment   After treatment   *P*-value
  ------------------ ------------------ ----------------- ---------------------------------------------------
  **CD31 (v/HPF)**                                        
  Range              35--46             5--10             \<0.001[a](#tfn3-ccid-5-001){ref-type="table-fn"}
  M ± SD             38.3 ± 2.5         7.6 ± 1.9         
  **CD34 (v/HPF)**                                        
  Range              40--48             8--13             \<0.001[a](#tfn3-ccid-5-001){ref-type="table-fn"}
  M ± SD             43.7 ± 2.3         11.5 ± 1.6        
  **BI**                                                  
  Range              4--6               0--1              \<0.001[a](#tfn3-ccid-5-001){ref-type="table-fn"}
  M ± SD             4.9 ± 0.3          1.4 ± 0.2         

**Note:** *P* is significant at \<0.05.

**Abbreviations:** BI, bacterial index; M, mean; SD, standard deviation, v/HPF, vessel/high power field.

###### 

CD31 and CD34 immunostaining and BI before and after treatment in both groups

                     Group A (n = 20)   Group B (n = 20)   *P*-value
  ------------------ ------------------ ------------------ ---------------------------------------------------
  **CD31 (v/HPF)**                                         
  Before treatment   39.1 ± 3.1         38.3 ± 2.5         0.37
  After treatment    16.5 ± 2.7         7.6 ± 1.9          \<0.001[a](#tfn5-ccid-5-001){ref-type="table-fn"}
  **CD34 (v/HPF)**                                         
  Before treatment   42.2 ± 3.1         43.7 ± 2.3         0.09
  After treatment    18.8 ± 2.4         11.5 ± 1.6         \<0.001[a](#tfn5-ccid-5-001){ref-type="table-fn"}
  **BI**                                                   
  Before treatment   5.1 ± 0.4          4.9 ± 0.3          0.08
  After treatment    2.3 ± 0.4          1.4 ± 0.2          \<0.001[a](#tfn5-ccid-5-001){ref-type="table-fn"}

**Note:** *P* is significant at \<0.05.

**Abbreviations:** BI, bacterial index; M, mean; SD, standard deviation, v/HPF, vessel/high power field.
